Gilead Sciences, Inc. (NASDAQ:GILD) Holdings Cut by Iberiabank Corp

Iberiabank Corp lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 29.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,062 shares of the biopharmaceutical company’s stock after selling 1,726 shares during the quarter. Iberiabank Corp’s holdings in Gilead Sciences were worth $313,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in GILD. Baldwin Brothers Inc. MA raised its holdings in shares of Gilead Sciences by 63.3% during the 1st quarter. Baldwin Brothers Inc. MA now owns 351 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 136 shares in the last quarter. Bainco International Investors bought a new position in Gilead Sciences in the 1st quarter worth $29,000. EPG Wealth Management LLC raised its holdings in Gilead Sciences by 186.7% in the 1st quarter. EPG Wealth Management LLC now owns 410 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 267 shares during the period. Harwood Advisory Group LLC bought a new position in Gilead Sciences in the 1st quarter worth $38,000. Finally, Modus Advisors LLC bought a new position in Gilead Sciences in the 2nd quarter worth $38,000. Institutional investors and hedge funds own 78.74% of the company’s stock.

Several analysts have issued reports on GILD shares. Cfra raised their price target on shares of Gilead Sciences from $71.00 to $74.00 and gave the stock a “sell” rating in a research report on Wednesday, April 29th. Piper Sandler decreased their price target on shares of Gilead Sciences from $90.00 to $85.00 and set an “overweight” rating on the stock in a research report on Friday. SunTrust Banks raised their price target on shares of Gilead Sciences from $73.00 to $74.00 and gave the stock a “hold” rating in a research report on Friday. Wells Fargo & Co decreased their price target on shares of Gilead Sciences from $87.00 to $76.00 and set an “equal weight” rating on the stock in a research report on Friday. Finally, Jefferies Financial Group restated a “buy” rating and issued a $97.00 price target on shares of Gilead Sciences in a research report on Tuesday, July 21st. Four research analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $79.63.

In related news, EVP Brett A. Pletcher sold 13,210 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the completion of the transaction, the executive vice president now owns 27,204 shares in the company, valued at $2,155,372.92. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Diane E. Wilfong sold 12,264 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $80.09, for a total transaction of $982,223.76. Following the completion of the transaction, the chief accounting officer now owns 23,685 shares of the company’s stock, valued at approximately $1,896,931.65. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,079 shares of company stock valued at $2,240,630. Corporate insiders own 0.13% of the company’s stock.

GILD opened at $69.53 on Friday. The company has a debt-to-equity ratio of 1.00, a current ratio of 3.04 and a quick ratio of 2.92. The company has a market cap of $90.73 billion, a price-to-earnings ratio of -289.70, a price-to-earnings-growth ratio of 2.43 and a beta of 0.70. The firm has a 50 day simple moving average of $75.47 and a 200 day simple moving average of $73.57. Gilead Sciences, Inc. has a fifty-two week low of $60.89 and a fifty-two week high of $85.97.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.11 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.57 by ($0.46). The business had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $5.24 billion. Gilead Sciences had a positive return on equity of 32.17% and a negative net margin of 1.16%. As a group, analysts expect that Gilead Sciences, Inc. will post 6.61 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.68 per share. This represents a $2.72 dividend on an annualized basis and a yield of 3.91%. Gilead Sciences’s dividend payout ratio is currently 44.30%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Featured Story: How is a buy-side analyst different from a sell-side analyst?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.